Parkinsonism Hyperpyrexia Syndrome (Q99242): Difference between revisions
From determinar.ia.br - Determine suas informações
Changed an Item |
Changed an Item |
||||||||||||||
| (One intermediate revision by the same user not shown) | |||||||||||||||
| Property / Knowledge Architect | |||||||||||||||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Collection date | |||||||||||||||
15 August 2026
| |||||||||||||||
| Property / Collection date: 15 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 15:54, 16 August 2026
The parkinsonism-hyperpyrexia syndrome (PHS) is a rare but potentially fatal complication seen in Parkinson's disease patients, most commonly following abrupt reduction or cessation of antiparkinson medications. Clinically it resembles neuroleptic malignant syndrome with: rigidity, pyrexia, reduced consciousness level, autonomic instability, and serum creatine kinase elevation.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | ID_211461908 |
||
| English | Parkinsonism Hyperpyrexia Syndrome |
The parkinsonism-hyperpyrexia syndrome (PHS) is a rare but potentially fatal complication seen in Parkinson's disease patients, most commonly following abrupt reduction or cessation of antiparkinson medications. Clinically it resembles neuroleptic malignant syndrome with: rigidity, pyrexia, reduced consciousness level, autonomic instability, and serum creatine kinase elevation. |
Statements
CID11:ID_211461908
0 references
dki-india-ID_211461908
0 references
Concluído
0 references
15 August 2026
0 references
